ABSTRACT
The usage of European Medicines Agency and United States Food and Drug Administration approved Lu-177 DOTATATE for the peptide receptor radionuclide therapies especially for the patients with Neuroendocrine tumors are accelarating continuously in the past years. Since the optimal treatment schedule concerning the Lu-177 DOTATATE PRRT was not standardized yet, it is a hot topic in research area. In this manuscript, the main aim is to summarize the current status of the requlations regarding to the patient-specific dosimetry in the Lu-177 DOTATATE PRRT including the results of the related studies. In addition, dosimetry approaches for the Lu-177 DOTATATE PRRT as well as their limitations were reviewed briefly.
References
1Kesner AL, Bodei L. Modern Radiopharmaceutical Dosimetry Should Include Robust Biodistribution Reporting. J Nucl Med 2018;59:1507-1509.
2Konijnenberg M, Herrmann K, Kobe C, et al. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging 2021;48:67-72.
3European Society of R. Summary of the European Directive 2013/59/Euratom: essentials for health professionals in radiology. Insights Imaging 2015;6:411-417.
4Flux G, Buscombe J, Officers, Council of the British Nuclear Medicine S. BNMS position statement on molecular radiotherapy. Nucl Med Commun 2021.
5Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008;35:1847-1856.
6Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-2130.
7Pettinato C, Sarnelli A, Di Donna M, et al. Ga-68 DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;35:72-79.
8Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013;40:800-816.
9Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in Peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47:1467-1475.
10Eberlein U, Cremonesi M, Lassmann M. Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive? J Nucl Med 2017;58:97S-103S.
11Strigari L, Benassi M, Chiesa C, Cremonesi M, Bodei L, D’Andrea M. Dosimetry in nuclear medicine therapy: radiobiology application and results. Q J Nucl Med Mol Imaging 2011;55:205-221.
12Stokke C, Gabina PM, Solny P, et al. Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force. EJNMMI Phys 2017;4:27.
13Ljungberg M, Celler A, Konijnenberg MW, et al. MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. J Nucl Med 2016;57:151-162.
14Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416-2423.
15Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46 Suppl 1:99S-106S.
16Menda Y, Madsen MT, O’Dorisio TM, et al. (90)Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. J Nucl Med 2018;59:1692-1698.
17Sundlov A, Sjogreen-Gleisner K, Svensson J, et al. Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging 2017;44:1480-1489.
18Garske-Roman U, Sändstrom M, Fross Baron K, et al. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging 2018;45:970-988.
19Del Prete M, Buteau FA, Arsenault F, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging 2019;46:728-742.
20Huizing DMV, de Wit-van der Veen BJ, Verheij M, Stokkel MPM. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review. EJNMMI research 2018;8:89.
21Lassmann M, Chiesa C, Flux G, Bardies M, Committee ED. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging 2011;38:192-200.
22Hanscheid H, Schirbel A, Hartrampf P, et al. Biokinetics and Dosimetry of [(177)Lu]Lu-Pentixather. J Nucl Med 2021.
23Haug AR. PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme? EJNMMI research 2020;10:35.
24Lassmann M, Eberlein U. Radiation Dosimetry Aspects of 177Lu. Curr Radiopharm 2015;8:139-144.
25Rinscheid A, Kletting P, Eiber M, Beer AJ, Glatting G. Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177Lu-PSMA therapy. Medical physics 2019;46:5861-5866.
26Belli ML, Mezzenga E, Di Iorio V, et al. A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods. J Vis Exp 2020.
27Hanscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days. J Nucl Med 2018;59:75-81.
28Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S-61S.
29Hindorf C, Glatting G, Chiesa C, Linden O, Flux G, Committee ED. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging 2010;37:1238-1250.
30Hagmarker L, Svensson J, Ryden T, et al. Bone marrow absorbed doses and correlations with hematological response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases. J Nucl Med 2019.
